农业百科

Toronto-based food manufacturing company NS/TX Industries has closed $10.5 million in Series A funding and non-dilutive grants to scale its alternative protein manufacturing platform and begin construction of a new automated assembly line.

In what’s shaping up to be a historic year for biotech initial public offerings, Parabilis Medicines (Nasdaq: PBLS) made its mark on Wall Street this past week by pricing the largest-ever IPO by a drug developer. This upsized offering raised an eye-popping $770.5 million in gross proceeds.

New Holland has received the Red Dot Design Award  for its T7 Standard Wheelbase tractor , one of the world’s most respected international recognitions for product design. The jury praised the tractor’s holistic redesign , which seamlessly combines style, functionality and advanced technology in the highly competitive 180–225 hp segment.

研究人员已经发现了一种抵抗机制 毒死蜱 em 甜菜夜蛾 该研究表明，SeOBP11蛋白介导了这种蛋白质与杀虫剂之间的直接联系。这种相互作用降低了产品的生物利用度，并在体内试验中降低了毛虫的死亡率。

EnergyDecentral 2026, the leading trade fair for decentralized energy supply, will take place from 10 to 13 November at the Hanover exhibition grounds alongside the EuroTier livstock exhibition and the “Inhouse Farming – Feed & Food Show.” Covering the entire value chain of sustainable energy production, EnergyDecentral offers an up-to-date technical and exhibition program.

Ice crystals can destroy crops. They are also a major headache for ice cream and other frozen foods, ruining texture, sh…

Meati Foods, once the poster child for mycelium steaks, collapsed after betting the farm on $300M submerged fermentation plants.

本周速览：本周全球生物制剂行业动作频频，中国企业雷力获得国际舞台背书；农业农村部上半年微生物肥料登记结果出炉；大洋彼岸，拜耳出手、诺和新元结盟，北美市场加速整合——制造端的突破正在把生物制剂从"实验室承诺"变成"田间现实"。

Montpellier-based Sensorion said it has filed clinical trial applications in France and Canada for SENS-601, also known as GJB2-GT, an AAV-based gene therapy designed to treat hearing loss caused by mutations in the GJB2 gene. The French medicines agency ANSM has granted the program a fast-track procedure, which Sensorion said should shorten the review period compared with the standard pathway. The company is also targeting an investigational new drug submission in the U.S. and a submission in Australia by the end of 2026.